Takeda Pharmaceutical and Cardurion Pharmaceuticals, a newly formed Cambridge, Massachusetts-based biotechnology company with research facilities in Shonan, Japan, have created a new cardiovascular development partnership. Cardurion is focused on the development of therapeutics for treating heart failure and other cardiovascular diseases.

Cardurion is led by two physician scientists with experience in cardiovascular science, medicine, and drug development–Daniel Bloomfield, MD, chief executive officer, and Michael Mendelsohn, MD, founder and executive chairman. Dr. Mendelsohn served as senior vice president and global franchise head, cardiovascular diseases with Merck Research Laboratories at Merck & Co. from 2010 to 2013.

Takeda will provide a 12-person cardiovascular research team from its Shonan, Japan site, including laboratory space, development resources, and licenses to a portfolio of preclinical-stage cardiovascular drug programs.

Source: Takeda Pharmaceutical